25 XP   0   0   10

Starpharma Holdings Ltd
Buy, Hold or Sell?

Let's analyse Starpharma together

PenkeI guess you are interested in Starpharma Holdings Ltd. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Starpharma Holdings Ltd. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Starpharma Holdings Ltd

I send you an email if I find something interesting about Starpharma Holdings Ltd.

Quick analysis of Starpharma (30 sec.)










What can you expect buying and holding a share of Starpharma? (30 sec.)

How much money do you get?

How much money do you get?
A$0.00
When do you have the money?
1 year
How often do you get paid?
10.0%

What is your share worth?

Current worth
A$0.08
Expected worth in 1 year
A$-0.05
How sure are you?
40.0%

+ What do you gain per year?

Total Gains per Share
A$-0.13
Return On Investment
-97.6%

For what price can you sell your share?

Current Price per Share
A$0.14
Expected price per share
A$0.12 - A$0.165
How sure are you?
50%

1. Valuation of Starpharma (5 min.)




Live pricePrice per Share (EOD)

A$0.14

Intrinsic Value Per Share

A$-0.35 - A$-0.31

Total Value Per Share

A$-0.27 - A$-0.23

2. Growth of Starpharma (5 min.)




Is Starpharma growing?

Current yearPrevious yearGrowGrow %
How rich?$22.6m$31.4m-$8.8m-39.0%

How much money is Starpharma making?

Current yearPrevious yearGrowGrow %
Making money-$10.1m-$10.4m$335.3k3.3%
Net Profit Margin-532.1%-345.0%--

How much money comes from the company's main activities?

3. Financial Health of Starpharma (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#568 / 1010

Most Revenue
#447 / 1010

Most Profit
#566 / 1010

Most Efficient
#745 / 1010

What can you expect buying and holding a share of Starpharma? (5 min.)

Welcome investor! Starpharma's management wants to use your money to grow the business. In return you get a share of Starpharma.

What can you expect buying and holding a share of Starpharma?

First you should know what it really means to hold a share of Starpharma. And how you can make/lose money.

Speculation

The Price per Share of Starpharma is A$0.135. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Starpharma.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Starpharma, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is A$0.08. Based on the TTM, the Book Value Change Per Share is A$-0.03 per quarter. Based on the YOY, the Book Value Change Per Share is A$-0.03 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is A$0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Starpharma.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 A$% of Price per ShareA$% of Price per ShareA$% of Price per ShareA$% of Price per ShareA$% of Price per Share
Usd Eps-0.02-18.3%-0.02-18.3%-0.03-18.9%-0.03-18.8%-0.02-16.2%
Usd Book Value Change Per Share-0.02-15.9%-0.02-15.9%-0.02-16.2%-0.01-4.3%0.00-1.3%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.0110.8%0.015.4%
Usd Total Gains Per Share-0.02-15.9%-0.02-15.9%-0.02-16.2%0.016.5%0.014.1%
Usd Price Per Share0.20-0.20-0.48-0.65-0.58-
Price to Earnings Ratio-8.17--8.17--18.88--25.83--18.31-
Price-to-Total Gains Ratio-9.41--9.41--21.92--23.35--8.37-
Price to Book Ratio3.67-3.67-6.30-9.57-8.25-
Price-to-Total Gains Ratio-9.41--9.41--21.92--23.35--8.37-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.0877365
Number of shares11397
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.01
Usd Book Value Change Per Share-0.02-0.01
Usd Total Gains Per Share-0.020.01
Gains per Quarter (11397 shares)-244.08100.09
Gains per Year (11397 shares)-976.32400.38
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-976-986666-266390
20-1953-19621332-531790
30-2929-29381998-7971190
40-3905-39142664-10621590
50-4882-48903329-13281990
60-5858-58663995-15932390
70-6834-68424661-18592790
80-7811-78185327-21243190
90-8787-87945993-23903590
100-9763-97706659-26553990

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.01.00.00.0%0.03.00.00.0%0.05.00.00.0%1.09.00.010.0%2.021.01.08.3%
Book Value Change Per Share0.01.00.00.0%1.02.00.033.3%1.04.00.020.0%4.06.00.040.0%11.013.00.045.8%
Dividend per Share0.00.01.00.0%1.00.02.033.3%1.00.04.020.0%1.00.09.010.0%1.00.023.04.2%
Total Gains per Share0.01.00.00.0%1.02.00.033.3%1.04.00.020.0%4.06.00.040.0%11.013.00.045.8%

Fundamentals of Starpharma

About Starpharma Holdings Ltd

Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. The company offers VivaGel BV, a non-antibiotic vaginal gel for the treatment of bacterial vaginosis and prevention of recurrent BV; VIRALEZE, an antiviral nasal spray; and VivaGel condom, an antiviral condom. It is also involved in the development of DEP cabazitaxel that is in Phase 2 clinical trial for the treatment of prostate and other cancers, DEP docetaxel that is in Phase 2 clinical trials for the treatment of colorectal and other cancers, DEP irinotecan that is in Phase 2 clinical trials f for the treatment of pancreatic and other cancers; and EP gemcitabine, DEP HER-2 ADC, and DEP HER-2 radiotherapy completed preclinical trials for the treatment of solid cancers. In addition, the company's DEP radiotheranostics development pipeline includes DEP HER2-zirconium, a HER2-targeted radio diagnostic for HER2-positive cancers, such as breast and gastric cancer; and HER2-targeted DEP SN38 ADC, a targeted ADC therapeutic for the treatment of human ovarian cancer. Starpharma Holdings Limited was incorporated in 1997 and is headquartered in Abbotsford, Australia.

Fundamental data was last updated by Penke on 2024-04-25 06:43:05.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is fair priced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Starpharma Holdings Ltd.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Starpharma earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Starpharma to the Biotechnology industry mean.
  • A Net Profit Margin of -532.1% means that $-5.32 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Starpharma Holdings Ltd:

  • The MRQ is -532.1%. The company is making a huge loss. -2
  • The TTM is -532.1%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-532.1%TTM-532.1%0.0%
TTM-532.1%YOY-345.0%-187.1%
TTM-532.1%5Y-599.7%+67.6%
5Y-599.7%10Y-1,130.5%+530.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-532.1%-207.2%-324.9%
TTM-532.1%-216.8%-315.3%
YOY-345.0%-282.3%-62.7%
5Y-599.7%-436.8%-162.9%
10Y-1,130.5%-597.3%-533.2%
1.1.2. Return on Assets

Shows how efficient Starpharma is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Starpharma to the Biotechnology industry mean.
  • -30.0% Return on Assets means that Starpharma generated $-0.30 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Starpharma Holdings Ltd:

  • The MRQ is -30.0%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -30.0%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-30.0%TTM-30.0%0.0%
TTM-30.0%YOY-24.4%-5.6%
TTM-30.0%5Y-29.1%-1.0%
5Y-29.1%10Y-27.1%-1.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-30.0%-13.3%-16.7%
TTM-30.0%-12.8%-17.2%
YOY-24.4%-11.6%-12.8%
5Y-29.1%-13.8%-15.3%
10Y-27.1%-15.6%-11.5%
1.1.3. Return on Equity

Shows how efficient Starpharma is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Starpharma to the Biotechnology industry mean.
  • -44.9% Return on Equity means Starpharma generated $-0.45 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Starpharma Holdings Ltd:

  • The MRQ is -44.9%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -44.9%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-44.9%TTM-44.9%0.0%
TTM-44.9%YOY-33.4%-11.5%
TTM-44.9%5Y-37.4%-7.5%
5Y-37.4%10Y-33.4%-4.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-44.9%-16.9%-28.0%
TTM-44.9%-16.1%-28.8%
YOY-33.4%-14.9%-18.5%
5Y-37.4%-19.3%-18.1%
10Y-33.4%-20.1%-13.3%

1.2. Operating Efficiency of Starpharma Holdings Ltd.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Starpharma is operating .

  • Measures how much profit Starpharma makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Starpharma to the Biotechnology industry mean.
  • An Operating Margin of -839.5% means the company generated $-8.40  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Starpharma Holdings Ltd:

  • The MRQ is -839.5%. The company is operating very inefficient. -2
  • The TTM is -839.5%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-839.5%TTM-839.5%0.0%
TTM-839.5%YOY-510.4%-329.1%
TTM-839.5%5Y-849.1%+9.6%
5Y-849.1%10Y-1,333.1%+484.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-839.5%-298.0%-541.5%
TTM-839.5%-238.5%-601.0%
YOY-510.4%-288.4%-222.0%
5Y-849.1%-486.2%-362.9%
10Y-1,333.1%-628.4%-704.7%
1.2.2. Operating Ratio

Measures how efficient Starpharma is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 9.40 means that the operating costs are $9.40 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Starpharma Holdings Ltd:

  • The MRQ is 9.395. The company is inefficient in keeping operating costs low. -1
  • The TTM is 9.395. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ9.395TTM9.3950.000
TTM9.395YOY6.104+3.291
TTM9.3955Y9.491-0.096
5Y9.49110Y15.490-5.999
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ9.3953.235+6.160
TTM9.3953.310+6.085
YOY6.1043.838+2.266
5Y9.4915.679+3.812
10Y15.4907.823+7.667

1.3. Liquidity of Starpharma Holdings Ltd.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Starpharma is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 3.26 means the company has $3.26 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Starpharma Holdings Ltd:

  • The MRQ is 3.256. The company is very able to pay all its short-term debts. +2
  • The TTM is 3.256. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ3.256TTM3.2560.000
TTM3.256YOY5.929-2.673
TTM3.2565Y5.777-2.521
5Y5.77710Y6.978-1.201
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.2563.863-0.607
TTM3.2564.169-0.913
YOY5.9295.337+0.592
5Y5.7776.122-0.345
10Y6.9786.434+0.544
1.3.2. Quick Ratio

Measures if Starpharma is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Starpharma to the Biotechnology industry mean.
  • A Quick Ratio of 3.00 means the company can pay off $3.00 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Starpharma Holdings Ltd:

  • The MRQ is 3.000. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 3.000. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ3.000TTM3.0000.000
TTM3.000YOY5.645-2.645
TTM3.0005Y5.603-2.604
5Y5.60310Y6.876-1.273
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.0003.504-0.504
TTM3.0003.991-0.991
YOY5.6455.371+0.274
5Y5.6036.088-0.485
10Y6.8766.395+0.481

1.4. Solvency of Starpharma Holdings Ltd.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Starpharma assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Starpharma to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.33 means that Starpharma assets are financed with 33.2% credit (debt) and the remaining percentage (100% - 33.2%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Starpharma Holdings Ltd:

  • The MRQ is 0.332. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.332. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.332TTM0.3320.000
TTM0.332YOY0.269+0.063
TTM0.3325Y0.216+0.116
5Y0.21610Y0.168+0.048
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.3320.339-0.007
TTM0.3320.337-0.005
YOY0.2690.271-0.002
5Y0.2160.368-0.152
10Y0.1680.388-0.220
1.4.2. Debt to Equity Ratio

Measures if Starpharma is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Starpharma to the Biotechnology industry mean.
  • A Debt to Equity ratio of 49.6% means that company has $0.50 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Starpharma Holdings Ltd:

  • The MRQ is 0.496. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.496. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.496TTM0.4960.000
TTM0.496YOY0.367+0.129
TTM0.4965Y0.288+0.208
5Y0.28810Y0.212+0.075
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4960.392+0.104
TTM0.4960.403+0.093
YOY0.3670.335+0.032
5Y0.2880.427-0.139
10Y0.2120.461-0.249

2. Market Valuation of Starpharma Holdings Ltd

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Starpharma generates.

  • Above 15 is considered overpriced but always compare Starpharma to the Biotechnology industry mean.
  • A PE ratio of -8.17 means the investor is paying $-8.17 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Starpharma Holdings Ltd:

  • The EOD is -3.557. Based on the earnings, the company is expensive. -2
  • The MRQ is -8.168. Based on the earnings, the company is expensive. -2
  • The TTM is -8.168. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-3.557MRQ-8.168+4.611
MRQ-8.168TTM-8.1680.000
TTM-8.168YOY-18.875+10.707
TTM-8.1685Y-25.831+17.663
5Y-25.83110Y-18.307-7.524
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-3.557-2.300-1.257
MRQ-8.168-2.656-5.512
TTM-8.168-2.718-5.450
YOY-18.875-4.145-14.730
5Y-25.831-6.258-19.573
10Y-18.307-6.315-11.992
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Starpharma Holdings Ltd:

  • The EOD is -3.930. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -9.024. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -9.024. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-3.930MRQ-9.024+5.094
MRQ-9.024TTM-9.0240.000
TTM-9.024YOY-21.781+12.756
TTM-9.0245Y-33.365+24.341
5Y-33.36510Y-28.906-4.459
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-3.930-2.974-0.956
MRQ-9.024-3.306-5.718
TTM-9.024-3.508-5.516
YOY-21.781-5.613-16.168
5Y-33.365-8.378-24.987
10Y-28.906-8.873-20.033
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Starpharma is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 3.67 means the investor is paying $3.67 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Starpharma Holdings Ltd:

  • The EOD is 1.598. Based on the equity, the company is underpriced. +1
  • The MRQ is 3.669. Based on the equity, the company is fair priced.
  • The TTM is 3.669. Based on the equity, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD1.598MRQ3.669-2.071
MRQ3.669TTM3.6690.000
TTM3.669YOY6.301-2.632
TTM3.6695Y9.575-5.906
5Y9.57510Y8.245+1.329
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD1.5981.914-0.316
MRQ3.6692.116+1.553
TTM3.6692.097+1.572
YOY6.3012.881+3.420
5Y9.5753.550+6.025
10Y8.2453.936+4.309
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Starpharma Holdings Ltd.

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Starpharma Holdings Ltd compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.033-0.0330%-0.034+2%-0.009-73%-0.003-92%
Book Value Per Share--0.0840.0840%0.117-28%0.106-21%0.110-23%
Current Ratio--3.2563.2560%5.929-45%5.777-44%6.978-53%
Debt To Asset Ratio--0.3320.3320%0.269+23%0.216+53%0.168+98%
Debt To Equity Ratio--0.4960.4960%0.367+35%0.288+72%0.212+134%
Dividend Per Share----0%-0%0.022-100%0.011-100%
Eps---0.038-0.0380%-0.039+3%-0.039+3%-0.034-11%
Free Cash Flow Per Share---0.034-0.0340%-0.034-1%-0.031-8%-0.033-5%
Free Cash Flow To Equity Per Share---0.036-0.0360%-0.026-27%-0.008-78%-0.008-77%
Gross Profit Margin--1.2081.2080%1.221-1%1.149+5%1.075+12%
Intrinsic Value_10Y_max---0.314--------
Intrinsic Value_10Y_min---0.355--------
Intrinsic Value_1Y_max---0.032--------
Intrinsic Value_1Y_min---0.035--------
Intrinsic Value_3Y_max---0.095--------
Intrinsic Value_3Y_min---0.107--------
Intrinsic Value_5Y_max---0.158--------
Intrinsic Value_5Y_min---0.179--------
Market Cap55625533.920-130%127732707.520127732707.5200%304910334.080-58%414513237.952-69%365892400.896-65%
Net Profit Margin---5.321-5.3210%-3.450-35%-5.997+13%-11.305+112%
Operating Margin---8.395-8.3950%-5.104-39%-8.491+1%-13.331+59%
Operating Ratio--9.3959.3950%6.104+54%9.491-1%15.490-39%
Pb Ratio1.598-130%3.6693.6690%6.301-42%9.575-62%8.245-56%
Pe Ratio-3.557+56%-8.168-8.1680%-18.875+131%-25.831+216%-18.307+124%
Price Per Share0.135-130%0.3100.3100%0.740-58%1.006-69%0.888-65%
Price To Free Cash Flow Ratio-3.930+56%-9.024-9.0240%-21.781+141%-33.365+270%-28.906+220%
Price To Total Gains Ratio-4.097+56%-9.407-9.4070%-21.925+133%-23.347+148%-8.367-11%
Quick Ratio--3.0003.0000%5.645-47%5.603-46%6.876-56%
Return On Assets---0.300-0.3000%-0.244-19%-0.291-3%-0.271-10%
Return On Equity---0.449-0.4490%-0.334-26%-0.374-17%-0.334-26%
Total Gains Per Share---0.033-0.0330%-0.034+2%0.014-344%0.009-486%
Usd Book Value--22626268.50022626268.5000%31450610.700-28%28495385.420-21%29467960.770-23%
Usd Book Value Change Per Share---0.021-0.0210%-0.022+2%-0.006-73%-0.002-92%
Usd Book Value Per Share--0.0550.0550%0.076-28%0.069-21%0.072-23%
Usd Dividend Per Share----0%-0%0.015-100%0.007-100%
Usd Eps---0.025-0.0250%-0.025+3%-0.025+3%-0.022-11%
Usd Free Cash Flow---9198684.600-9198684.6000%-9097950.100-1%-8418284.680-8%-8783138.540-5%
Usd Free Cash Flow Per Share---0.022-0.0220%-0.022-1%-0.020-8%-0.021-5%
Usd Free Cash Flow To Equity Per Share---0.023-0.0230%-0.017-27%-0.005-78%-0.005-77%
Usd Market Cap36151034.495-130%83013486.61783013486.6170%198161226.119-58%269392153.345-69%237793471.342-65%
Usd Price Per Share0.088-130%0.2010.2010%0.481-58%0.654-69%0.577-65%
Usd Profit---10163136.200-10163136.2000%-10498484.600+3%-10279988.220+1%-8931835.660-12%
Usd Revenue--1910056.1001910056.1000%3042831.800-37%2223047.940-14%1872296.910+2%
Usd Total Gains Per Share---0.021-0.0210%-0.022+2%0.009-344%0.006-486%
 EOD+3 -5MRQTTM+0 -0YOY+10 -245Y+10 -2610Y+7 -29

4.2. Fundamental Score

Let's check the fundamental score of Starpharma Holdings Ltd based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-3.557
Price to Book Ratio (EOD)Between0-11.598
Net Profit Margin (MRQ)Greater than0-5.321
Operating Margin (MRQ)Greater than0-8.395
Quick Ratio (MRQ)Greater than13.000
Current Ratio (MRQ)Greater than13.256
Debt to Asset Ratio (MRQ)Less than10.332
Debt to Equity Ratio (MRQ)Less than10.496
Return on Equity (MRQ)Greater than0.15-0.449
Return on Assets (MRQ)Greater than0.05-0.300
Total4/10 (40.0%)

4.3. Technical Score

Let's check the technical score of Starpharma Holdings Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose0.130
Total0/1 (0.0%)



Latest Balance Sheet

Balance Sheet of 2023-06-30. Currency in AUD. All numbers in thousands.

Summary
Total Assets52,086
Total Liabilities17,271
Total Stockholder Equity34,815
 As reported
Total Liabilities 17,271
Total Stockholder Equity+ 34,815
Total Assets = 52,086

Assets

Total Assets52,086
Total Current Assets47,122
Long-term Assets4,964
Total Current Assets
Cash And Cash Equivalents 35,180
Net Receivables 8,235
Inventory 2,773
Other Current Assets 934
Total Current Assets  (as reported)47,122
Total Current Assets  (calculated)47,122
+/- 0
Long-term Assets
Property Plant Equipment 4,964
Other Assets 0
Long-term Assets  (as reported)4,964
Long-term Assets  (calculated)4,964
+/- 0

Liabilities & Shareholders' Equity

Total Current Liabilities14,473
Long-term Liabilities2,798
Total Stockholder Equity34,815
Total Current Liabilities
Short-term Debt 5,522
Short Long Term Debt 4,778
Accounts payable 6,615
Other Current Liabilities 2,333
Total Current Liabilities  (as reported)14,473
Total Current Liabilities  (calculated)19,248
+/- 4,775
Long-term Liabilities
Long term Debt Total 2,750
Other Liabilities 48
Long-term Liabilities  (as reported)2,798
Long-term Liabilities  (calculated)2,798
+/-0
Total Stockholder Equity
Common Stock240,715
Retained Earnings -234,199
Accumulated Other Comprehensive Income 28,299
Total Stockholder Equity (as reported)34,815
Total Stockholder Equity (calculated)34,815
+/-0
Other
Capital Stock240,715
Cash And Equivalents33,519
Cash and Short Term Investments 35,180
Common Stock Shares Outstanding 409,035
Current Deferred Revenue3
Liabilities and Stockholders Equity 52,086
Net Debt -26,908
Net Invested Capital 39,593
Net Tangible Assets 34,815
Net Working Capital 32,649
Property Plant and Equipment Gross 8,092
Short Long Term Debt Total 8,272



Balance Sheet

Currency in AUD. All numbers in thousands.

 Trend2023-06-302022-06-302021-06-302020-06-302019-06-302018-06-302017-06-302016-06-302015-06-302014-06-302013-06-302012-06-302011-06-302010-06-302009-06-302008-06-302007-06-302006-06-302005-06-302004-06-302003-06-302002-06-302001-06-302000-06-301999-06-301998-06-30
> Total Assets 
0
0
29,053
26,025
18,859
10,715
18,491
12,500
25,013
30,423
24,653
28,847
37,567
29,807
54,268
48,550
36,862
44,383
59,039
66,591
58,511
48,859
39,078
73,238
66,175
52,086
52,08666,17573,23839,07848,85958,51166,59159,03944,38336,86248,55054,26829,80737,56728,84724,65330,42325,01312,50018,49110,71518,85926,02529,05300
   > Total Current Assets 
0
0
28,936
25,789
17,838
8,459
16,242
8,354
17,108
11,408
9,255
13,176
24,230
19,941
44,865
39,332
28,598
35,080
50,276
65,678
57,453
47,809
36,676
70,755
60,658
47,122
47,12260,65870,75536,67647,80957,45365,67850,27635,08028,59839,33244,86519,94124,23013,1769,25511,40817,1088,35416,2428,45917,83825,78928,93600
       Cash And Cash Equivalents 
0
0
28,079
25,412
17,434
7,892
15,658
8,166
14,284
10,073
7,482
11,595
22,851
18,918
42,812
33,840
24,028
30,848
45,972
61,188
51,319
41,251
30,054
60,500
49,918
35,180
35,18049,91860,50030,05441,25151,31961,18845,97230,84824,02833,84042,81218,91822,85111,5957,48210,07314,2848,16615,6587,89217,43425,41228,07900
       Net Receivables 
0
0
698
305
150
420
471
43
2,664
899
1,403
1,481
1,323
870
1,917
5,314
4,416
4,011
4,126
4,206
6,097
6,080
6,087
8,439
7,836
8,235
8,2357,8368,4396,0876,0806,0974,2064,1264,0114,4165,3141,9178701,3231,4811,4038992,6644347142015030569800
       Other Current Assets 
0
0
158
72
253
148
113
145
160
436
370
100
56
153
136
178
154
221
178
284
37
79
41
95
80
934
9348095417937284178221154178136153561003704361601451131482537215800
   > Long-term Assets 
0
0
117
236
1,022
2,256
2,248
4,146
7,905
19,016
15,398
15,671
13,337
9,866
9,403
9,218
8,264
9,303
8,763
913
1,058
1,050
2,402
2,483
5,517
4,964
4,9645,5172,4832,4021,0501,0589138,7639,3038,2649,2189,4039,86613,33715,67115,39819,0167,9054,1462,2482,2561,02223611700
       Property Plant Equipment 
0
0
117
236
1,022
2,005
1,556
1,233
1,431
1,111
758
447
219
280
414
411
509
910
690
913
1,058
1,050
2,402
2,483
5,517
4,964
4,9645,5172,4832,4021,0501,0589136909105094114142802194477581,1111,4311,2331,5562,0051,02223611700
       Goodwill 
0
0
0
0
0
0
0
0
0
1,755
1,547
1,835
1,747
1,387
1,461
1,606
1,581
1,939
2,005
0
0
0
0
0
0
0
00000002,0051,9391,5811,6061,4611,3871,7471,8351,5471,755000000000
       Intangible Assets 
0
0
0
0
0
0
0
0
4,087
16,031
13,093
13,389
11,371
8,199
7,528
7,201
6,174
6,454
6,068
0
0
0
0
0
0
0
00000006,0686,4546,1747,2017,5288,19911,37113,38913,09316,0314,08700000000
       Other Assets 
0
0
0
0
74
0
0
0
0
43
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000430000740000
> Total Liabilities 
0
0
199
1,110
1,593
1,472
898
2,534
3,697
4,699
4,270
3,348
2,723
2,114
5,617
2,582
3,911
6,825
9,615
5,607
5,234
6,464
7,752
10,938
17,782
17,271
17,27117,78210,9387,7526,4645,2345,6079,6156,8253,9112,5825,6172,1142,7233,3484,2704,6993,6972,5348981,4721,5931,11019900
   > Total Current Liabilities 
0
0
199
1,110
1,593
1,269
755
2,365
3,033
3,260
3,715
3,143
2,665
2,041
5,435
2,459
3,844
6,769
9,575
5,521
5,164
6,426
6,697
10,429
10,231
14,473
14,47310,23110,4296,6976,4265,1645,5219,5756,7693,8442,4595,4352,0412,6653,1433,7153,2603,0332,3657551,2691,5931,11019900
       Short-term Debt 
0
0
0
0
0
60
60
60
142
69
124
133
160
49
40
25
27
30
18
23
26
26
604
692
695
5,522
5,5226956926042626231830272540491601331246914260606000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
75
48
18
70
49
0
0
0
0
4,778
4,778000049701848750000000000000000
       Accounts payable 
0
0
160
1,016
1,208
670
429
1,647
1,898
1,855
1,623
1,764
1,346
940
4,156
1,208
2,586
5,481
8,210
4,034
3,023
4,098
4,394
6,711
6,762
6,615
6,6156,7626,7114,3944,0983,0234,0348,2105,4812,5861,2084,1569401,3461,7641,6231,8551,8981,6474296701,2081,01616000
       Other Current Liabilities 
0
0
39
93
214
257
266
280
331
356
417
316
530
703
842
1,115
1,187
1,184
1,347
1,453
1,708
1,875
1,262
2,614
2,308
2,333
2,3332,3082,6141,2621,8751,7081,4531,3471,1841,1871,115842703530316417356331280266257214933900
   > Long-term Liabilities 
0
0
0
0
0
204
144
169
664
1,440
555
205
58
73
182
123
67
56
40
86
70
38
1,055
509
7,551
2,798
2,7987,5515091,05538708640566712318273582055551,44066416914420400000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
18
0
47
23
0
970
475
7,494
2,750
2,7507,4944759700234701800000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
89
349
226
134
45
58
56
82
48
19
38
40
39
47
38
85
34
57
48
485734853847394038194882565845134226349890000000
> Total Stockholder Equity
0
0
28,853
24,916
17,010
9,243
17,592
9,966
21,316
25,724
20,383
25,499
34,844
27,693
48,651
45,968
32,951
37,558
49,424
60,984
53,277
42,395
31,326
62,300
48,393
34,815
34,81548,39362,30031,32642,39553,27760,98449,42437,55832,95145,96848,65127,69334,84425,49920,38325,72421,3169,96617,5929,24317,01024,91628,85300
   Common Stock
0
0
33,065
33,034
33,034
33,034
46,822
46,822
65,375
76,227
78,667
85,640
101,766
105,399
139,171
140,081
140,349
160,884
193,512
193,549
193,583
193,621
193,661
240,630
240,669
240,715
240,715240,669240,630193,661193,621193,583193,549193,512160,884140,349140,081139,171105,399101,76685,64078,66776,22765,37546,82246,82233,03433,03433,03433,06500
   Retained Earnings Total Equity00000000000000000000000000
   Accumulated Other Comprehensive Income 
0
0
-23
-86
-259
-47
13
-28
497
1,299
1,009
3,279
2,876
1,022
1,866
3,502
4,852
7,874
9,787
10,896
13,440
16,775
20,340
24,077
26,285
28,299
28,29926,28524,07720,34016,77513,44010,8969,7877,8744,8523,5021,8661,0222,8763,2791,0091,299497-2813-47-259-86-2300
   Capital Surplus 00000000000000000000000000
   Treasury Stock00000000000000000000000000
   Other Stockholders Equity 
0
0
23
86
259
0
0
0
0
0
0
0
0
0
0
0
4,852
-1,385
-1,118
10,896
13,440
16,775
-10,986
-38,223
-22,108
-6,516
-6,516-22,108-38,223-10,98616,77513,44010,896-1,118-1,3854,85200000000000259862300



Balance Sheet

Currency in AUD. All numbers in thousands.




Cash Flow

Currency in AUD. All numbers in thousands.




Income Statement

Currency in AUD. All numbers in thousands.


Latest Income Statement (annual, 2023-06-30)

Gross Profit (+$)
totalRevenue2,939
Cost of Revenue-1,717
Gross Profit1,2231,223
 
Operating Income (+$)
Gross Profit1,223
Operating Expense-25,896
Operating Income-24,673-24,673
 
Operating Expense (+$)
Research Development18,870
Selling General Administrative3,768
Selling And Marketing Expenses3,258
Operating Expense25,89625,896
 
Net Interest Income (+$)
Interest Income1,269
Interest Expense-0
Other Finance Cost-0
Net Interest Income1,269
 
Pretax Income (+$)
Operating Income-24,673
Net Interest Income1,269
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-23,269-26,077
EBIT - interestExpense = -24,673
-23,269
-15,638
Interest Expense0
Earnings Before Interest and Taxes (EBIT)-24,673-23,269
Earnings Before Interest and Taxes (EBITDA)-23,480
 
After tax Income (+$)
Income Before Tax-23,269
Tax Provision-0
Net Income From Continuing Ops-15,638-23,269
Net Income-15,638
Net Income Applicable To Common Shares-15,638
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses27,612
Total Other Income/Expenses Net1,404-1,269
 

Technical Analysis of Starpharma
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Starpharma. The general trend of Starpharma is UNKNOWN with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Starpharma's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator StateBullish trend Bearish trend
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Starpharma Holdings Ltd.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 0.15 < 0.155 < 0.165.

The bearish price targets are: 0.125 > 0.125 > 0.12.

Tweet this
Starpharma Holdings Ltd Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Starpharma Holdings Ltd. The current mas is .

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Starpharma Holdings Ltd Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Starpharma Holdings Ltd.

Starpharma Holdings Ltd Daily Moving Average Convergence/Divergence (MACD) ChartStarpharma Holdings Ltd Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Starpharma Holdings Ltd. The current adx is .

Starpharma Holdings Ltd Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Starpharma Holdings Ltd.

Starpharma Holdings Ltd Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Starpharma Holdings Ltd.

Starpharma Holdings Ltd Daily Relative Strength Index (RSI) ChartStarpharma Holdings Ltd Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Starpharma Holdings Ltd.

Starpharma Holdings Ltd Daily Stochastic Oscillator ChartStarpharma Holdings Ltd Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Starpharma Holdings Ltd.

Starpharma Holdings Ltd Daily Commodity Channel Index (CCI) ChartStarpharma Holdings Ltd Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Starpharma Holdings Ltd.

Starpharma Holdings Ltd Daily Chande Momentum Oscillator (CMO) ChartStarpharma Holdings Ltd Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Starpharma Holdings Ltd.

Starpharma Holdings Ltd Daily Williams %R ChartStarpharma Holdings Ltd Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Starpharma Holdings Ltd.

Starpharma Holdings Ltd Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Starpharma Holdings Ltd.

Starpharma Holdings Ltd Daily Average True Range (ATR) ChartStarpharma Holdings Ltd Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Starpharma Holdings Ltd.

Starpharma Holdings Ltd Daily On-Balance Volume (OBV) ChartStarpharma Holdings Ltd Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Starpharma Holdings Ltd.

Starpharma Holdings Ltd Daily Money Flow Index (MFI) ChartStarpharma Holdings Ltd Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Starpharma Holdings Ltd.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-12-01MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-04MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-05CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-12-06DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2023-12-07DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-08CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-12STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-13STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-14MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-15CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-18SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-19ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-21RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2023-12-27STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-08MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-10SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-12STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-15CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-01-16STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-22WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-23DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-25STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-01-29DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-30DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-31DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-01STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-02DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-05DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-06DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-07DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-02-12MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-13MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-19STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-20WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-02-21STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-22CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-23STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-26CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-28STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-01CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-03-04MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-03-06STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-07STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-12MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-14STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-15CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-19SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-22SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-03-25SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-26STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-03-28CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-02DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-03STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-05DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-08DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-04-10WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-04-11STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-04-15CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-16DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-17STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-18MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-19DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-23SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-24STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).

6.3. Candlestick Patterns

Starpharma Holdings Ltd Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Starpharma Holdings Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose0.130
Total0/1 (0.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Starpharma with someone you think should read this too:
  • Are you bullish or bearish on Starpharma? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Starpharma? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Starpharma Holdings Ltd

I send you an email if I find something interesting about Starpharma Holdings Ltd.


Comments

How you think about this?

Leave a comment

Stay informed about Starpharma Holdings Ltd.

Receive notifications about Starpharma Holdings Ltd in your mailbox!